In April ----, the Chilean government announced plans to introduce Medicine Act - to strengthen the purchasing power of the Central Purchasing Agency (CENABAST), establish a permanent stock of generic drugs and biosimilars, to reduce medicine prices and improve the transparency of medicine price regulation. In June ----, Helsinn and Grunenthal Group signed an exclusive agreement for the registration, marketing, promotion and sale of Akynzeo by Grupo Grunenthal Chile. ...The drug is already approved in the US, the EU, Switzerland, Israel and Australia. In July ----, French orphan drug developer Onxeo entered into an exclusive licensing agreement with Pint Pharma for the commercialisation of Beleodaq (belinostat), Onxeo s pan-HDAC inhibitor for peripheral T-cell lymphoma (PTCL), in key South American countries. The drug is being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) in the Chilean market. Beleodaq is approved in the US and has been marketed by Spectrum Pharmaceuticals since
...In April ----, five of the largest local pharmaceutical companies, Grunenthal, Corporacion Farmaceutica Recalcine (acquired by Abbott in ----), Laboratorio Chile (a subsidiary of Teva) and Bago, formed a new union to represent their interests - the Association of Local Production of Medicines, PROLMED. These companies, accounting for -- of overall sales volumes in the Chile, chose to break away from the Asociacion Industrial de Laboratorios Farmaceuticos (ASILFA) - representing local and regional generics manufacturers - and the Chamber of the Pharmaceutical Industry in Chile (CIF) - which represents the multinational innovative drugmakers. ...In April ----, five of the largest local pharmaceutical companies, Grunenthal, Corporacion Farmaceutica Recalcine (acquired by Abbott in ----), Laboratorio Chile (a subsidiary of Teva) and Bago, formed a new union to represent their interests - the Association of Local Production of Medicines, PROLMED. These companies, accounting for -- of overall sales volumes in the Chile, chose to break away from the Asociacion Industrial de Laboratorios Farmaceuticos (ASILFA) - representing local and regional generics manufacturers - and the Chamber of the Pharmaceutical Industry in Chile (CIF) - which represents the multinational innovative drugmakers. ...These companies, accounting for -- of overall sales volumes in the Chile, chose to break away from the Asociacion Industrial de Laboratorios Farmaceuticos (ASILFA) - representing local and regional generics manufacturers - and the Chamber of the Pharmaceutical Industry in Chile (CIF) - which represents the multinational innovative drugmakers.
...In BMI s Q--- Risk/Reward Index, Chile has moved up by one place to fourth out of -- markets in the Americas matrix with a slightly lower score of --.- out of ---. President Bachelet s centre-left government will increasingly focus on improving Chile s regulatory framework, placing an emphasis on raising standards for quality assurance compliance potentially raising operating costs. ...In BMI s Q--- Risk/Reward Index, Chile has moved up by one place to fourth out of -- markets in the Americas matrix with a slightly lower score of --.- out of ---. President Bachelet s centre-left government will increasingly focus on improving Chile s regulatory framework, placing an emphasis on raising standards for quality assurance compliance potentially raising operating costs. However, the senate health committee s decision to markedly improve public spending on healthcare with the Ricarte Soto Law highlights growing improvement in the population s access to many services. ...